logo
Share SHARE
FONT-SIZE Plus   Neg

Genentech Says Perjeta Combination Increased Survival In Breast Cancer Patients

Genentech, a member of the Roche Group (RHHBY), Friday said new data from a late-stage study showed combining its breast cancer drug Perjeta with another combination significantly improved overall survival in patients.

The company noted that people with HER2-positive metastatic breast cancer, or mBC, lived significantly longer when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone.

Hal Barron, chief medical officer and head, Global Product Development stated, "We are pleased that Perjeta helped people with HER2-positive metastatic breast cancer live longer and lengthened the time they lived without their disease worsening."

Perjeta is a personalized medicine that targets the HER2 receptor - a protein found in high quantities on the outside of cancer cells in HER2-positive cancers.

Genentech said the median progression-free survival improved by 6.1 months from 12.4 months for people who received Herceptin and chemotherapy plus placebo to 18.5 months for those who received Perjeta, Herceptin and chemotherapy.

The FDA recently approved Perjeta in combination with Herceptin and docetaxel chemotherapy to treat people who have not received prior anti-HER2 therapy. Roche has submitted a marketing authorization application to the European Medicines Agency for Perjeta for people with previously untreated HER2-positive mBC.

The international, Phase III, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety profile of Perjeta combined with Herceptin and docetaxel chemotherapy in 808 people.

Genentech said it will submit these data for presentation at an upcoming medical meeting.

RHHBY closed Thursday's regular trading at $42.01.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
German automaker Daimler AG reported Friday lower profit in its third quarter, while revenues increased on strong unit sales. Looking ahead, for fiscal 2017, the company projects significantly higher EBIT, revenues and unit sales. The Mercedes-Benz Cars, Daimler Buses, and Daimler Financial Services divisions expect significantly higher revenues. Ericsson reported Friday wider than expected third-quarter loss on higher charges and weak sales. However, adjusted gross margin improved and the company sees positive effects on gross margin in 2018. Ericsson further said the general market conditions continue to be tough, yet it is starting to see some encouraging improvements. Ericsson shares were gaining around 5 percent in Stockholm. Target Corp. said it now plans to remodel more of its existing supercenters and open smaller stores in cities, aiming to win back shoppers in the highly competitive retail world. By the end of 2020, the company plans to remodel more than 1,000 of its 1,800 existing stores.
comments powered by Disqus
Follow RTT